Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs

Sun, Tao; Hu, Gang; Li, Ming

doi:10.1016/j.ejphar.2008.11.036

Cited by 46 publications

(88 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study as well as our previous ones (Sun et al, 2009;Li et al, 2010), we have observed no differences in behavioral responsiveness to OLZ and CLZ in the induction phase (ie, the repeated drug treatment period), but differences in the expression phase (ie, the challenge test). For example, during the drug treatment period in both the CAR and the PCP-induced hyperlocomotion model (ie, the induction phase), repeated OLZ and CLZ treatment persistently inhibited avoidance response and PCP-induced hyperlocomotion.…”

Section: Discussionsupporting

confidence: 43%

“…For example, during the drug treatment period in both the CAR and the PCP-induced hyperlocomotion model (ie, the induction phase), repeated OLZ and CLZ treatment persistently inhibited avoidance response and PCP-induced hyperlocomotion. OLZ and CLZ did not differ from each other (Sun et al, 2009;Li et al, 2010). Only in the later challenge test (ie, the expression phase) did we observe the pattern differences between OLZ and CLZ.…”

Section: Discussionmentioning

confidence: 80%

“…Besides the CAR test, it has been reported in a catalepsy test (Lanis and Schmidt, 2001;Amtage and Schmidt, 2003;Klein and Schmidt, 2003), a PCP-induced hyperlocomotion test (Sun et al, 2009;Zhang and Li, 2012), a PPI of acoustic startle procedure (Li et al, 2011), an operant responding procedure (Varvel et al, 2002), as well as in the metabolic effect (Boyda et al, 2012). In contrast, CLZ often induces a tolerance effect .…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, repeated treatment of clozapine (CLZ) does not cause an apparent sensitization or tolerance during the induction phase (Sun et al, 2009;Li et al, 2010). But in the expression phase when all rats are injected with a low dose of CLZ, rats previously treated with CLZ exhibit a tolerance effect, as they often make significantly more avoidance responses and exhibit higher PCP-induced hyperlocomotion than those that are treated with CLZ for the first time .…”

Section: Introductionmentioning

confidence: 94%

“…Using such a paradigm, we show that repeated treatment of haloperidol and olanzapine (OLZ) induce a sensitization effect in both the induction and expression phases (Li et al, 2009b;Li et al, 2009a;Sun et al, 2009;Li et al, 2010;Mead and Li, 2010;Zhao et al, 2012). In contrast, repeated treatment of clozapine (CLZ) does not cause an apparent sensitization or tolerance during the induction phase (Sun et al, 2009;Li et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Olanzapine Sensitization and Clozapine Tolerance: From Adolescence to Adulthood in the Conditioned Avoidance Response Model

Qiao

2012

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

Disruption of conditioned avoidance response (CAR) in rodents is one trademark feature of many antipsychotic drugs. In adult rats, repeated olanzapine (OLZ) treatment causes an enhanced disruption of avoidance response (sensitization), whereas repeated clozapine (CLZ) treatment causes a decreased disruption (tolerance). The present study addressed (1) whether OLZ sensitization and CLZ tolerance can be induced in adolescent rats, and (2) the extent to which OLZ sensitization and CLZ tolerance induced in adolescence persists into adulthood. Male adolescent Sprague-Dawley rats (approximate postnatal days (BP) 43-47) were first treated with OLZ (1.0 or 2.0 mg/kg, subcutaneously (sc)) or CLZ (10 or 20 mg/kg, sc) daily for 5 consecutive days in the CAR model. They were then tested for the expression of OLZ sensitization or CLZ tolerance either in adolescence (BP 50) or after they matured into adults (BP 76 and 92) in a challenge test during which all rats were injected with either a lower dose of OLZ (0.5 mg/kg) or CLZ (5.0 mg/kg). When tested in adolescence, rats previously treated with OLZ showed a stronger inhibition of CAR than those previously treated with vehicle (ie, sensitization). In contrast, rats previously treated with CLZ showed a weaker inhibition of CAR than those previously treated with vehicle (ie, tolerance). When tested in adulthood, the OLZ sensitization was still detectable at both time points (BP 76 and 92), whereas the CLZ tolerance was only detectable on BP 76, and only manifested in the intertrial crossing. Performance in the prepulse inhibition and fear-induced 22 kHz ultrasonic vocalizations in adulthood were not altered by adolescence drug treatment. Collectively, these findings suggest that atypical antipsychotic treatment during adolescence can induce a long-term specific alteration in antipsychotic effect that persists into adulthood despite the brain maturation. As antipsychotic drugs are being increasingly used in children and adolescents in the past two decades, findings from this study are important for understanding the impacts of adolescent antipsychotic treatment on the brain and behavioral developments. This work also has implications for clinical practice involving adolescence antipsychotic treatments in terms of drug choice, drug dose, and schedule.

show abstract

Section: Discussionsupporting

confidence: 43%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Olanzapine Sensitization and Clozapine Tolerance: From Adolescence to Adulthood in the Conditioned Avoidance Response Model

Qiao

2012

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit gene GRIN2B and clinical response to clozapine

Taylor

Tiwari

Lieberman

et al. 2016

Human Psychopharmacology

View full text Add to dashboard Cite

Objective Approximately 30% of patients with schizophrenia fail to respond to antipsychotic therapy and are classified as having treatment‐resistant schizophrenia. Clozapine is the most efficacious drug for treatment‐resistant schizophrenia and may deliver superior therapeutic effects partly by modulating glutamate neurotransmission. Response to clozapine is highly variable and may depend on genetic factors as indicated by twin studies. We investigated eight polymorphisms in the N‐methyl‐d‐aspartate glutamate receptor subunit gene GRIN2B with response to clozapine. Methods GRIN2B variants were genotyped using standard TaqMan procedures in 175 European patients with schizophrenia deemed resistant or intolerant to treatment. Response was assessed using change in Brief Psychiatric Rating Scale scores following six months of clozapine therapy. Categorical and continuous response was assessed using chi‐squared test and analysis of covariance, respectively. Results No associations were observed between the variants and response to clozapine. A‐allele carriers of rs1072388 responded marginally better to clozapine therapy than GG‐homozygotes; however, the difference was not statistically significant (p = 0.067, uncorrected). Conclusions Our findings do not support a role for these GRIN2B variants in altering response to clozapine in our sample. Investigation of additional glutamate variants in clozapine response is warranted. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Differential effects of acute amphetamine and phencyclidine treatment and withdrawal from repeated amphetamine or phencyclidine treatment on social interaction and social memory in rats

Munro

2012

PsyCh Journal

Self Cite

View full text Add to dashboard Cite

Although animal models based on amphetamine (AMPH) or phencyclidine (PCP) treatment have been used extensively to study the neurobiological and behavioral characteristics of schizophrenia, there are conflicting reports regarding their validity in modeling the negative symptoms and cognitive deficits of schizophrenia. The present study examined how acute AMPH or PCP treatment (Experiment 1) and withdrawal from repeated AMPH treatment (Experiment 2) or PCP treatment (Experiment 3) affects social behavior and social recognition memory in male Sprague‐Dawley rats. Each subject was tested on two consecutive days. On the first day, the rats were tested four times (5 min/each) at 10‐min intervals with the same partner rat (termed “AAAA” day). One day later, the rats were tested with the previous partner in the first three sessions and with a new partner rat in the final session (termed “AAAB” day). The results show that acute AMPH treatment (1.5 mg/kg, sc) significantly reduced the time spent on social interaction, but did not affect social recognition on the first day. Acute AMPH only disrupted social recognition on the second day of drug testing. In contrast, acute PCP treatment (2.0 mg/kg, sc) had no effect on time spent on social interaction, but did significantly disrupt social recognition on both days. Withdrawal from repeated AMPH (3.0 mg/kg/day for 7 days, ip) or PCP (5.0 mg/kg/twice daily for 7 days, ip) treatment did not affect social interaction or social recognition, indicating a lack of long‐term detrimental effect of repeated AMPH or PCP treatment. These results suggest that acute AMPH treatment at a low dose (1.5 mg/kg) may be useful in modeling social withdrawal symptoms of schizophrenia, whereas acute PCP treatment at a similar dose range (2.0 mg/kg) may be useful in modeling the social cognitive deficit of schizophrenia.

show abstract

Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs

Cited by 46 publications

References 52 publications

Olanzapine Sensitization and Clozapine Tolerance: From Adolescence to Adulthood in the Conditioned Avoidance Response Model

Olanzapine Sensitization and Clozapine Tolerance: From Adolescence to Adulthood in the Conditioned Avoidance Response Model

Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit gene GRIN2B and clinical response to clozapine

Differential effects of acute amphetamine and phencyclidine treatment and withdrawal from repeated amphetamine or phencyclidine treatment on social interaction and social memory in rats

Contact Info

Product

Resources

About